A new drug to treat Alzheimer's disease has been developed

Alzheimer's disease has proved promising in a new experimental treatment program, which has no harmful side effects, US researchers reported on Wednesday. The study, published in the journal Science Translational Medicine, based on a small sample of 32 people, led to two broader clinical trials and is currently being studied with more than 3,000 participants. This treatment uses a compound known as verubecestat and was developed by American Pharmaceuticals using recombinant rat proteins. It reduces the level of protein called beta-amyloid by blocking the BACE1 enzyme.

In people with Alzheimer’s disease, protein aggregates form plaques that damage the brain, affecting people & apos; s cognitive abilities, especially memory. The enzyme plays a key role in the production of proteins. 32 patients who participated in the first clinical trial were diagnosed with mild to moderate Alzheimer's disease. Pharmaceutical laboratories are working to develop compounds that prevent or even reverse these plaque formations. The products used to neutralize BACEI enzymes so far have very deleterious side effects, such as liver damage or further neurodegeneration. But, says Matthew Kennedy, Ph.D., of the Merck Research Laboratory in northeastern New Jersey, Verubecestat does not. The researchers found that one or two doses of verubecestat compound sufficient to reduce protein levels without causing side effects.

Two phase III trials are currently underway and will be completed in July 2017 to evaluate the efficacy of verubecestat. If the results are good, the compound can be made into pills within two to three years. According to the forecast, in the United States the baby boomer generation (birth peak) more than 80 years of age, by 2050 suffering from Alzheimer's disease may be more than 28 million people. The World Health Organization says there are 36 million people in the world suffering from some form of dementia, most of them suffering from Alzheimer's disease.

If no effective treatment is available in the next few years, the figure is expected to double by 2030 to over 65.7 million and double again by 2050 if without effective treatment. Flarebio provides good-quality recombinant proteins such as recombinant LARGE at great prices.